{"id":243,"date":"2026-04-18T23:05:39","date_gmt":"2026-04-19T06:05:39","guid":{"rendered":"https:\/\/taurusmeds.com\/articles\/pediatric-trt-fda-approvals\/"},"modified":"2026-04-18T23:05:42","modified_gmt":"2026-04-19T06:05:42","slug":"pediatric-trt-fda-approvals","status":"publish","type":"post","link":"https:\/\/taurusmeds.com\/articles\/pediatric-trt-fda-approvals\/","title":{"rendered":"Pediatric Testosterone Therapy FDA Approvals, Evidence Gaps, and Care Standards"},"content":{"rendered":"<style>\n  a, a:visited { color: #F1471D !important; text-decoration: none; }\n  a:hover, a:focus { text-decoration: underline; }\n  section.ta-section { margin: 32px 0; }\n  .wp-block-table-of-contents ol { margin-left: 1.25rem; }\n<\/style>\n<section class=\"ta-section wp-block-group\">\n<h2 class=\"wp-block-heading\">Pediatric Testosterone Therapy FDA Approvals, Evidence Gaps, and Care Standards<\/h2>\n<p class=\"wp-block-paragraph\">Which testosterone treatments are actually FDA-approved for adolescents, and why most others are adult-only. Understand growth plate risks, monitoring, and where new studies may lead.<\/p>\n<\/section>\n<section class=\"ta-section wp-block-group\">\n<p class=\"wp-block-paragraph\"><strong>Estimated reading time:<\/strong> 8 minutes<\/p>\n<\/section>\n<section class=\"ta-section wp-block-group\">\n<h3 class=\"wp-block-heading\" id=\"h-key-takeaways\">Key takeaways<\/h3>\n<ul class=\"wp-block-list\">\n<li>Only testosterone enanthate injections and subcutaneous pellets carry FDA indications related to delayed puberty in carefully selected males or for hypogonadism occurring before puberty; most modern TRT products are adult-only.<\/li>\n<li>These pediatric indications predate current trial standards and would not meet today\u2019s evidentiary expectations.<\/li>\n<li>Labels warn of accelerated bone age and premature epiphyseal closure; bone-age X-rays about every six months are recommended when used in adolescents.<\/li>\n<li>Kyzatrex (oral testosterone undecanoate) has an FDA postmarketing requirement to study pediatric males 12 to &lt;18\u2014an effort to fill evidence gaps.<\/li>\n<li>Clinicians and families should confirm the narrow FDA-recognized indications, involve pediatric endocrinology, monitor growth plates, and avoid off-label pediatric use of other formulations.<\/li>\n<\/ul>\n<\/section>\n<section class=\"ta-section wp-block-group wp-block-table-of-contents\">\n<h3 class=\"wp-block-heading\" id=\"h-toc\">Table of contents<\/h3>\n<ol>\n<li><a href=\"#h-fda-approvals\">What the FDA Actually Approves for Pediatric Use Today<\/a><\/li>\n<li><a href=\"#h-legacy-approvals\">Why These Legacy Pediatric Approvals Don\u2019t Look Like Modern Trials<\/a><\/li>\n<li><a href=\"#h-risks\">Risks Unique to Adolescents: Bone Age Acceleration and Growth Plates<\/a><\/li>\n<li><a href=\"#h-kyzatrex-pmr\">Kyzatrex\u2019s Pediatric PMR: A Modern Study to Close a Long\u2011Standing Gap<\/a><\/li>\n<li><a href=\"#h-practical-implications\">Practical Implications for Clinicians and Families<\/a><\/li>\n<li><a href=\"#h-evolving-standards\">How Modern Standards May Evolve<\/a><\/li>\n<li><a href=\"#h-conclusion\">A Balanced Conclusion<\/a><\/li>\n<\/ol>\n<\/section>\n<section class=\"ta-section wp-block-group\">\n<p class=\"wp-block-paragraph\">Testosterone therapy in adolescents sits at a careful intersection of endocrinology, growth, and regulation. The FDA does allow select testosterone formulations for pediatric use\u2014but only in narrow circumstances and based largely on historical approvals that would not meet today\u2019s evidentiary standards. This article reviews what\u2019s actually FDA\u2011approved for delayed puberty or pediatric hypogonadism, why the evidence base looks different from modern trials, the specific risks relevant to adolescents, and what to watch as new pediatric studies are required for newer products.<\/p>\n<h3 class=\"wp-block-heading\" id=\"h-fda-approvals\">What the FDA Actually Approves for Pediatric Use Today<\/h3>\n<p class=\"wp-block-paragraph\">Despite the broad public conversation about testosterone therapy, pediatric approvals are narrow:<\/p>\n<ul class=\"wp-block-list\">\n<li>Testosterone enanthate (TE) injections and subcutaneous testosterone pellets have FDA labeling that permits use \u201cfor stimulating puberty in carefully selected males with clear evidence of delayed puberty,\u201d or for hypogonadism occurring prior to puberty.<\/li>\n<li>The labels emphasize cautious patient selection and monitoring. They recommend bone\u2011age (hand\/wrist) radiographs about every six months during treatment to watch for accelerated bone maturation.<\/li>\n<li>In contrast, nearly all other testosterone replacement therapy (TRT) products\u2014transdermal gels and patches, short\u2011acting nasal formulations, injectable testosterone undecanoate, and oral testosterone undecanoate\u2014explicitly state that safety and efficacy have not been established in males younger than 18 years. In other words, they\u2019re adult\u2011only, with pediatric use not supported by current labeling.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">This matters because clinical practice and direct\u2011to\u2011consumer marketing for adult hypogonadism can be mistaken for a green light in adolescents. It isn\u2019t. For pediatric patients, FDA\u2011recognized options are limited to TE injections and pellets, and even those require vigilant growth monitoring and specialist oversight.<\/p>\n<h3 class=\"wp-block-heading\" id=\"h-legacy-approvals\">Why These Legacy Pediatric Approvals Don\u2019t Look Like Modern Trials<\/h3>\n<p class=\"wp-block-paragraph\">The TE and pellet approvals trace back to an earlier regulatory era. Historically, the concept was straightforward: if a child has hypogonadism or markedly delayed puberty, androgen replacement can stimulate the development of secondary sexual characteristics. That principle underpinned the approvals\u2014without the type of well\u2011controlled, adequately powered pediatric efficacy and safety trials that the FDA typically expects today.<\/p>\n<p class=\"wp-block-paragraph\">Key context:<\/p>\n<ul class=\"wp-block-list\">\n<li>Many testosterone products were introduced before the Drug Efficacy Study Implementation (DESI) modernized standards for proof of efficacy. As a result, historical approvals leaned more on pharmacology and clinical experience than on contemporary randomized trial designs.<\/li>\n<li>Modern adult TRT approvals tend to rely on pharmacokinetic (PK) \u201cnormalization\u201d\u2014showing that a product achieves serum testosterone levels within adult reference ranges\u2014rather than on hard clinical outcomes. In pediatrics, however, growth, maturation timing, bone health, and long\u2011term development carry different stakes and require dedicated study.<\/li>\n<li>Because the original pediatric approvals didn\u2019t go through today\u2019s trial rigor, we lack robust, contemporary data on long\u2011term growth outcomes, optimal regimens across hypogonadism subtypes, or comparative effectiveness among formulations in adolescents.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">In short, the existence of a pediatric indication for TE and pellets reflects regulatory history, not a comprehensive modern evidence base.<\/p>\n<h3 class=\"wp-block-heading\" id=\"h-risks\">Risks Unique to Adolescents: Bone Age Acceleration and Growth Plates<\/h3>\n<p class=\"wp-block-paragraph\">The clearest label warning for adolescent testosterone exposure is the risk of accelerated bone maturation leading to premature epiphyseal closure. In practical terms, the growth plates in long bones can fuse earlier than they otherwise would, potentially limiting final adult height.<\/p>\n<p class=\"wp-block-paragraph\">What this means for care:<\/p>\n<ul class=\"wp-block-list\">\n<li>Monitoring is not optional. Bone\u2011age X\u2011rays roughly every six months are part of responsible care when using TE injections or pellets in adolescents. Radiographic evidence of advancement beyond expected maturity may prompt reassessment.<\/li>\n<li>\u201cImproper use\u201d is a real concern. Initiating therapy in the absence of clear hypogonadism or carefully selected delayed puberty\u2014or using supraphysiologic amounts\u2014raises the risk of rapid skeletal maturation without proportional linear growth.<\/li>\n<li>Individual variation matters. Adolescents are in a dynamic developmental window with evolving endocrine, skeletal, and psychosocial trajectories. Decisions about whether and when to start or adjust therapy require pediatric endocrinology expertise and careful discussion of benefits, risks, and uncertainties.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">Other androgen\u2011related adverse effects (like acne, mood changes, or hematologic shifts) may occur, but the growth plate risk is uniquely consequential for lifelong stature and underpins the strict monitoring recommendations.<\/p>\n<h3 class=\"wp-block-heading\" id=\"h-kyzatrex-pmr\">Kyzatrex\u2019s Pediatric PMR: A Modern Study to Close a Long\u2011Standing Gap<\/h3>\n<p class=\"wp-block-paragraph\">Kyzatrex (oral testosterone undecanoate) was approved by the FDA in 2022 for adult hypogonadism. Importantly for pediatrics, its approval includes a postmarketing requirement to conduct a pediatric trial in males ages 12 to &lt;18 with primary or secondary hypogonadism. The PMR milestones specified at approval were:<\/p>\n<ul class=\"wp-block-list\">\n<li>Study protocol submission: June 2023<\/li>\n<li>Trial completion: December 2023<\/li>\n<li>Final report submission: March 2024<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">Why this matters:<\/p>\n<ul class=\"wp-block-list\">\n<li>It\u2019s a deliberate move by the FDA to generate modern pediatric data where little currently exists, particularly for oral testosterone formulations.<\/li>\n<li>A dedicated pediatric study\u2014if well designed and completed\u2014could clarify dosing strategies, safety signals (including growth plate impacts), PK targets appropriate for adolescents, and short\u2011term clinical effects (e.g., Tanner staging progress).<\/li>\n<li>Even with new data, a pediatric indication is not guaranteed. The FDA could conclude that safety\/efficacy remain insufficient, that benefits apply only to specific subgroups, or that additional studies are needed.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">As of the 2022 approval, results were not available. Families and clinicians should check the latest FDA communications to confirm whether the PMR has been completed, what it found, and whether it changes labeling or recommendations.<\/p>\n<h3 class=\"wp-block-heading\" id=\"h-practical-implications\">Practical Implications for Clinicians and Families<\/h3>\n<p class=\"wp-block-paragraph\">Given the tight regulatory framework and evidence gaps, a conservative, standards\u2011based approach is warranted.<\/p>\n<p class=\"wp-block-paragraph\">If a pediatric patient is being evaluated for delayed puberty or suspected hypogonadism:<\/p>\n<ul class=\"wp-block-list\">\n<li>Confirm the diagnosis with a pediatric endocrinologist. The differential for delayed puberty is broad, and timing of maturation varies. Specialist input helps determine whether observation, non\u2011androgen strategies, or androgen therapy is appropriate.<\/li>\n<li>Verify the FDA\u2011approved pediatric options. As of now, only TE injections and subcutaneous pellets have pediatric\u2011relevant indications for stimulating puberty in carefully selected cases. Most other TRT formulations explicitly lack pediatric safety\/efficacy data.<\/li>\n<li>Discuss growth plate monitoring upfront. Bone\u2011age radiographs about every six months are part of the label recommendations to mitigate the risk of premature epiphyseal closure.<\/li>\n<li>Align expectations with uncertainties. Short\u2011term progression of secondary sexual characteristics may be achievable, but the long\u2011term impact on adult height, cardiometabolic health, fertility, and psychosocial outcomes remains under\u2011studied by modern standards.<\/li>\n<li>Approach off\u2011label pediatric use of adult\u2011only products with caution. The absence of established safety and efficacy is meaningful; approval in adults does not imply suitability for adolescents.<\/li>\n<li>Reassess regularly. Adolescence is a moving target. Periodic review of growth velocity, bone age, Tanner staging, labs, and psychosocial factors supports course corrections as needed.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">Questions families can bring to a pediatric endocrinology visit:<\/p>\n<ul class=\"wp-block-list\">\n<li>Is my child\u2019s presentation consistent with constitutional delay, or is there evidence of primary\/secondary hypogonadism?<\/li>\n<li>If testosterone is considered, why TE injections or pellets versus other formulations? What\u2019s FDA\u2011approved for pediatric use?<\/li>\n<li>How will bone maturation and growth be monitored? What would trigger a change in plan?<\/li>\n<li>What short\u2011term benefits should we expect, and what are the known and unknown risks?<\/li>\n<li>How does the plan align with my child\u2019s developmental, social, and athletic life?<\/li>\n<li>If newer data (e.g., from required pediatric studies) become available, how would that impact the treatment approach?<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">For adult\u2011focused TRT clinics, including services like Taurus Meds, the practical boundary is clear: pediatric therapy requires pediatric endocrinology expertise, pediatric\u2011specific monitoring, and adherence to FDA\u2011recognized indications. Adult TRT workflows and formulations shouldn\u2019t be repurposed for adolescents.<\/p>\n<h3 class=\"wp-block-heading\" id=\"h-evolving-standards\">How Modern Standards May Evolve<\/h3>\n<p class=\"wp-block-paragraph\">Two regulatory dynamics will shape the future of pediatric TRT:<\/p>\n<ul class=\"wp-block-list\">\n<li>Pediatric research requirements and incentives: For newer products approved in adults, the FDA can require pediatric assessments or studies if a therapy might be relevant to children. That\u2019s the case with Kyzatrex. As more data emerge, labeling could expand\u2014or remain restricted\u2014based on benefits and risks demonstrated in adolescents.<\/li>\n<li>Outcome expectations: Pediatric trials increasingly emphasize clinically meaningful outcomes\u2014growth trajectories, bone age progression relative to chronological age, pubertal staging, safety signals\u2014rather than PK alone. This could raise the evidentiary bar for future pediatric indications across formulations.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">Key open questions:<\/p>\n<ul class=\"wp-block-list\">\n<li>Will modern pediatric trials confirm safe, effective regimens that preserve adult height potential?<\/li>\n<li>Are certain hypogonadism subtypes better suited to specific formulations or schedules?<\/li>\n<li>Can findings from adult PK\u2011normalization translate safely to adolescents, or do youth\u2011specific targets and endpoints need to be defined?<\/li>\n<li>What is the long\u2011term safety profile of contemporary formulations started during adolescence?<\/li>\n<\/ul>\n<h3 class=\"wp-block-heading\" id=\"h-conclusion\">A Balanced Conclusion<\/h3>\n<p class=\"wp-block-paragraph\">Pediatric TRT is not a simple extension of adult practice. Today, only testosterone enanthate injections and testosterone pellets hold FDA indications relevant to delayed puberty in carefully selected cases, and those approvals stem from an earlier regulatory era. The label\u2011mandated focus on bone\u2011age monitoring reflects a real and potentially irreversible risk: premature closure of the growth plates.<\/p>\n<p class=\"wp-block-paragraph\">Newer products approved for adults\u2014like Kyzatrex\u2014are now carrying postmarketing pediatric study requirements, which is a welcome step toward an evidence base aligned with modern standards. Until high\u2011quality pediatric data are available and acted upon through updated labeling, clinicians and families should stay within the narrow FDA\u2011recognized indications, avoid off\u2011label pediatric use of adult\u2011only formulations, and partner closely with pediatric endocrinologists.<\/p>\n<p class=\"wp-block-paragraph\">For families exploring care options, the safest path is a measured one\u2014grounded in diagnosis, respectful of growth biology, and responsive to new data as it emerges.<\/p>\n<\/section>\n<section class=\"ta-section wp-block-group\">\n<h3 class=\"wp-block-heading\" id=\"h-disclaimer\">Disclaimer<\/h3>\n<p class=\"wp-block-paragraph\">This article is for informational purposes only and is not a substitute for professional medical advice. Testosterone therapy in adolescents should be managed by qualified healthcare professionals\u2014ideally pediatric endocrinologists\u2014based on individual clinical circumstances and current FDA\u2011approved labeling.<\/p>\n<\/section>\n<section class=\"ta-section wp-block-group\">\n<h3 class=\"wp-block-heading\" id=\"h-sources\">Sources<\/h3>\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/testosterone-information\">FDA Testosterone Information<\/a><\/li>\n<li><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/213953Orig1s000SumR.pdf\">Kyzatrex (testosterone undecanoate) NDA Summary Review (2022)<\/a><\/li>\n<li><a href=\"https:\/\/www.fda.gov\/media\/123591\/download?attachment\">FDA Androgen-Related Safety Communication (PDF)<\/a><\/li>\n<\/ul>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>Pediatric Testosterone Therapy FDA Approvals, Evidence Gaps, and Care Standards Which testosterone treatments are actually FDA-approved for adolescents, and why most others are adult-only. Understand growth plate risks, monitoring, and where new studies may lead. Estimated reading time: 8 minutes Key takeaways Only testosterone enanthate injections and subcutaneous pellets carry FDA indications related to delayed [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-243","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/posts\/243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/comments?post=243"}],"version-history":[{"count":1,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/posts\/243\/revisions"}],"predecessor-version":[{"id":244,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/posts\/243\/revisions\/244"}],"wp:attachment":[{"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/media?parent=243"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/categories?post=243"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/tags?post=243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}